USP18 and carcinoma: This finding is consistent with the conclusions of Zheng Rui et al., who reported that USP18 downregulation can reduce the protein stability of PD-L1 and weaken the PD-L1/PD-1 interaction, thereby enhancing the antitumor immune response and ultimately inhibiting bladder tumorigenesis [57].